Unfortunately, the downregulation of CB1 activity by a universally active CB1 inverse agonist elicited psychiatric side effects (e.g., anxiety, depression, and suicide) resulting in market withdrawal (60). The gene discussed is CNR1; the disease is depressive disorder.